Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors von Bahleda, R., Meric-Bernstam, F., Goyal, L., Tran, B., He, Y., Yamamiya, I., Benhadji, K.A., Matos, I., Arkenau, H.-T.

Volltext

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer von Massard, C., Azaro, A., Soria, J.-C., Lassen, U., Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B.K.R., Yuen, E.S.M., Benhadji, K.A., Rodon, J.

Volltext

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma von Kelley, R K, Gane, E, Assenat, E, Siebler, J, Galle, P R, Merle, P, Hourmand, I O, Cleverly, A, Zhao, Y, Gueorguieva, I, Lahn, M, Faivre, S, Benhadji, K A, Giannelli, G

Volltext

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors von Massard, C., Cassier, P. A., Azaro, A., Anderson, B., Yuen, E., Yu, D., Oakley, G., Benhadji, K. A., Pant, S.

Volltext

Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients von Mir, O., Watson, S., Massard, C., Le Cesne, A., Benhadji, K.A., Soria, J.C.

Volltext

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma von Even, C., Lassen, U., Merchan, J., Le Tourneau, C., Soria, J-C, Ferte, C., Ricci, F., Diener, J. T., Yuen, E., Smith, C., Oakley, G. J., Benhadji, K. A., Massard, Christophe

Volltext

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells von Benhadji, K A, Serova, M, Ghoul, A, Cvitkovic, E, Le Tourneau, C, Ogbourne, S M, Lokiec, F, Calvo, F, Hammel, P, Faivre, S, Raymond, E

Volltext

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer von Van Cutsem, E., Hochster, H., Shitara, K., Mayer, R., Ohtsu, A., Falcone, A., Yoshino, T., Doi, T., Ilson, D.H., Arkenau, H.-T., George, B., Benhadji, K.A., Makris, L., Tabernero, J.

Volltext

Galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC) von Tijeras-Raballand, A, Le Bitoux, M.A, Maillard, A, Albuquerque, M, Colnot, N, Barral, M, Dohan, A, Bonnin, P, Pocard, M, Benhadji, K, Paradis, V, Raymond, E, Harari, A, Faivre, S, De Gramont, A

Volltext

The serine‐threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells von Kheirallah, S, Fruchon, S, Ysebaert, L, Blanc, A, Capilla, F, Marrot, A, AlSaati, T, Frenois, F X, Benhadji, K A, Fournié, J J, Laurent, G, Bezombes, C

Volltext

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells von Serova, M, Galmarini, C M, Ghoul, A, Benhadji, K, Green, S R, Chiao, J, Faivre, S, Cvitkovic, E, Le Tourneau, C, Calvo, F, Raymond, E

Volltext

Preclinical and Clinical Development of Novel Agents That Target the Protein Kinase C Family von Serova, Maria, Ghoul, Aïda, Benhadji, Karim A., Cvitkovic, Esteban, Faivre, Sandrine, Calvo, Fabien, Lokiec, François, Raymond, Eric

Volltext

3O IGSF8 is an innate immune checkpoint and cancer immunotherapy target von Benhadji, K., Li, Y., Wu, X., Liu, H., Xiao, X., Ding, Q., Xie, B., Sheng, C., Zheng, R., Yu, Q., Hu, X., Liu, X.S., Xiao, T.

Volltext

1000MO A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors von Wentzel, K., Peguero, J., Kummar, S., Lorusso, P., Mehnert, J.M., Spira, A.I., Naing, A., Hamid, O., Mehmi, I., Benhadji, K., Alland, L., Hu, X., Xiao, H., Bao, X., Chen, J., Gong, Y., Liu, X.S.

Volltext

467P Dose escalation of TAS-117 in patients with advanced solid tumors von Rodon, J., Arkenau, H-T., Funchain, P., Hervieu, A., Gao, L., Liu, M., Halim, A., Mina, M., Takahashi, O., Benhadji, K., Delaloge, S.

Volltext

58P Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2 - A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene f... von Valle, J.W., Hollebecque, A., Furuse, J., Goyal, L., Meric-Bernstam, F., Morlock, R., He, Y., Benhadji, K., Bridgewater, J.

Volltext

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway von Herbertz, Stephan, Sawyer, J Scott, Stauber, Anja J, Gueorguieva, Ivelina, Driscoll, Kyla E, Estrem, Shawn T, Cleverly, Ann L, Desaiah, Durisala, Guba, Susan C, Benhadji, Karim A, Slapak, Christopher A, Lahn, Michael M

Volltext

Double diffusive convection in a shallow porous cavity filled with a non-newtonian fluid von Benhadji, K., Vasseur, P.

Volltext

A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours von Hollebecque, Antoine, Houédé, Nadine, Cohen, Ezra E.W, Massard, Christophe, Italiano, Antoine, Westwood, Paul, Bumgardner, William, Miller, Joel, Brail, Les H, Benhadji, Karim A, Soria, Jean-Charles

Volltext

POSA354 Patient-Reported Outcomes in Futibatinib-Treated Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusions/Rearrangements: Results from the Foenix-CCA2 Study von Bridgewater, JA, Hollebecque, A, Furuse, J, Goyal, L, Meric-Bernstam, F, Epstein, RS, Morlock, R, Salimi, T, Wacheck, V, Liu, M, Benhadji, K, Valle, JW

Volltext